A phase II study of oxaliplatin and prednisone for patients with relapsed or refractory marginal zone lymphoma: Consortium for Improving Survival of Lymphoma trial

Sung Yong Oh, Won Seog Kim, Jinseok Kim, Yee Soo Chae, Gyeong Won Lee, Hyeon Seok Eom, Hun Mo Ryoo, Suee Lee, Seok Jin Kim, Dok Hyun Yoon, Jong Ho Won, Junshik Hong, Jinny Park, Sang Min Lee, Jung Yong Hong, Eunkyung Park, Hyo Jung Kim, Deok Hwan Yang, Hyo Jin Kim, Cheolwon Suh

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Overall, more than 50% of marginal zone lymphoma (MZL) patients experience a relapse within 10 years. This phase II trial was conductedto assess the efficacy and safety of oxaliplatin-prednisone (Ox-P) chemotherapy for patients with relapsed or refractory MZL. Patients received oxaliplatin 130 mg/m2 on day 1 and prednisone 100 mg/day on days 1-5 of each cycle. A total of 38 patients were enrolled. The median age of the 34 (16 males, 18 females) evaluated patients was 53 (range = 27-74) years. There were seven complete responses (20.6%) and 15 partial responses (44.1%) (Overall response rate = 64.7%). No treatment-related deaths occurred. The median progression-free survival was 14.2 months (95% CI = 2.1-26.3 months); 3-year overall survival rate was 77.7%. Thus, salvage Ox-P chemotherapy for patients with relapsed or refractory MZL at the stated dosage and schedule showed moderate clinical activity and was considerable in very few selected patients (NCT01068392).

Original languageEnglish
Pages (from-to)1406-1412
Number of pages7
JournalLeukemia and Lymphoma
Volume57
Issue number6
DOIs
Publication statusPublished - 2016 Jun 2

Fingerprint

oxaliplatin
Prednisone
Lymphoma
Survival
Drug Therapy
Disease-Free Survival

All Science Journal Classification (ASJC) codes

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Oh, Sung Yong ; Kim, Won Seog ; Kim, Jinseok ; Chae, Yee Soo ; Lee, Gyeong Won ; Eom, Hyeon Seok ; Ryoo, Hun Mo ; Lee, Suee ; Kim, Seok Jin ; Yoon, Dok Hyun ; Won, Jong Ho ; Hong, Junshik ; Park, Jinny ; Lee, Sang Min ; Hong, Jung Yong ; Park, Eunkyung ; Kim, Hyo Jung ; Yang, Deok Hwan ; Kim, Hyo Jin ; Suh, Cheolwon. / A phase II study of oxaliplatin and prednisone for patients with relapsed or refractory marginal zone lymphoma : Consortium for Improving Survival of Lymphoma trial. In: Leukemia and Lymphoma. 2016 ; Vol. 57, No. 6. pp. 1406-1412.
@article{5e06fd8c18d3425b89ac1190f30eb0ce,
title = "A phase II study of oxaliplatin and prednisone for patients with relapsed or refractory marginal zone lymphoma: Consortium for Improving Survival of Lymphoma trial",
abstract = "Overall, more than 50{\%} of marginal zone lymphoma (MZL) patients experience a relapse within 10 years. This phase II trial was conductedto assess the efficacy and safety of oxaliplatin-prednisone (Ox-P) chemotherapy for patients with relapsed or refractory MZL. Patients received oxaliplatin 130 mg/m2 on day 1 and prednisone 100 mg/day on days 1-5 of each cycle. A total of 38 patients were enrolled. The median age of the 34 (16 males, 18 females) evaluated patients was 53 (range = 27-74) years. There were seven complete responses (20.6{\%}) and 15 partial responses (44.1{\%}) (Overall response rate = 64.7{\%}). No treatment-related deaths occurred. The median progression-free survival was 14.2 months (95{\%} CI = 2.1-26.3 months); 3-year overall survival rate was 77.7{\%}. Thus, salvage Ox-P chemotherapy for patients with relapsed or refractory MZL at the stated dosage and schedule showed moderate clinical activity and was considerable in very few selected patients (NCT01068392).",
author = "Oh, {Sung Yong} and Kim, {Won Seog} and Jinseok Kim and Chae, {Yee Soo} and Lee, {Gyeong Won} and Eom, {Hyeon Seok} and Ryoo, {Hun Mo} and Suee Lee and Kim, {Seok Jin} and Yoon, {Dok Hyun} and Won, {Jong Ho} and Junshik Hong and Jinny Park and Lee, {Sang Min} and Hong, {Jung Yong} and Eunkyung Park and Kim, {Hyo Jung} and Yang, {Deok Hwan} and Kim, {Hyo Jin} and Cheolwon Suh",
year = "2016",
month = "6",
day = "2",
doi = "10.3109/10428194.2015.1099650",
language = "English",
volume = "57",
pages = "1406--1412",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "6",

}

Oh, SY, Kim, WS, Kim, J, Chae, YS, Lee, GW, Eom, HS, Ryoo, HM, Lee, S, Kim, SJ, Yoon, DH, Won, JH, Hong, J, Park, J, Lee, SM, Hong, JY, Park, E, Kim, HJ, Yang, DH, Kim, HJ & Suh, C 2016, 'A phase II study of oxaliplatin and prednisone for patients with relapsed or refractory marginal zone lymphoma: Consortium for Improving Survival of Lymphoma trial', Leukemia and Lymphoma, vol. 57, no. 6, pp. 1406-1412. https://doi.org/10.3109/10428194.2015.1099650

A phase II study of oxaliplatin and prednisone for patients with relapsed or refractory marginal zone lymphoma : Consortium for Improving Survival of Lymphoma trial. / Oh, Sung Yong; Kim, Won Seog; Kim, Jinseok; Chae, Yee Soo; Lee, Gyeong Won; Eom, Hyeon Seok; Ryoo, Hun Mo; Lee, Suee; Kim, Seok Jin; Yoon, Dok Hyun; Won, Jong Ho; Hong, Junshik; Park, Jinny; Lee, Sang Min; Hong, Jung Yong; Park, Eunkyung; Kim, Hyo Jung; Yang, Deok Hwan; Kim, Hyo Jin; Suh, Cheolwon.

In: Leukemia and Lymphoma, Vol. 57, No. 6, 02.06.2016, p. 1406-1412.

Research output: Contribution to journalArticle

TY - JOUR

T1 - A phase II study of oxaliplatin and prednisone for patients with relapsed or refractory marginal zone lymphoma

T2 - Consortium for Improving Survival of Lymphoma trial

AU - Oh, Sung Yong

AU - Kim, Won Seog

AU - Kim, Jinseok

AU - Chae, Yee Soo

AU - Lee, Gyeong Won

AU - Eom, Hyeon Seok

AU - Ryoo, Hun Mo

AU - Lee, Suee

AU - Kim, Seok Jin

AU - Yoon, Dok Hyun

AU - Won, Jong Ho

AU - Hong, Junshik

AU - Park, Jinny

AU - Lee, Sang Min

AU - Hong, Jung Yong

AU - Park, Eunkyung

AU - Kim, Hyo Jung

AU - Yang, Deok Hwan

AU - Kim, Hyo Jin

AU - Suh, Cheolwon

PY - 2016/6/2

Y1 - 2016/6/2

N2 - Overall, more than 50% of marginal zone lymphoma (MZL) patients experience a relapse within 10 years. This phase II trial was conductedto assess the efficacy and safety of oxaliplatin-prednisone (Ox-P) chemotherapy for patients with relapsed or refractory MZL. Patients received oxaliplatin 130 mg/m2 on day 1 and prednisone 100 mg/day on days 1-5 of each cycle. A total of 38 patients were enrolled. The median age of the 34 (16 males, 18 females) evaluated patients was 53 (range = 27-74) years. There were seven complete responses (20.6%) and 15 partial responses (44.1%) (Overall response rate = 64.7%). No treatment-related deaths occurred. The median progression-free survival was 14.2 months (95% CI = 2.1-26.3 months); 3-year overall survival rate was 77.7%. Thus, salvage Ox-P chemotherapy for patients with relapsed or refractory MZL at the stated dosage and schedule showed moderate clinical activity and was considerable in very few selected patients (NCT01068392).

AB - Overall, more than 50% of marginal zone lymphoma (MZL) patients experience a relapse within 10 years. This phase II trial was conductedto assess the efficacy and safety of oxaliplatin-prednisone (Ox-P) chemotherapy for patients with relapsed or refractory MZL. Patients received oxaliplatin 130 mg/m2 on day 1 and prednisone 100 mg/day on days 1-5 of each cycle. A total of 38 patients were enrolled. The median age of the 34 (16 males, 18 females) evaluated patients was 53 (range = 27-74) years. There were seven complete responses (20.6%) and 15 partial responses (44.1%) (Overall response rate = 64.7%). No treatment-related deaths occurred. The median progression-free survival was 14.2 months (95% CI = 2.1-26.3 months); 3-year overall survival rate was 77.7%. Thus, salvage Ox-P chemotherapy for patients with relapsed or refractory MZL at the stated dosage and schedule showed moderate clinical activity and was considerable in very few selected patients (NCT01068392).

UR - http://www.scopus.com/inward/record.url?scp=84946949637&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84946949637&partnerID=8YFLogxK

U2 - 10.3109/10428194.2015.1099650

DO - 10.3109/10428194.2015.1099650

M3 - Article

C2 - 26413982

AN - SCOPUS:84946949637

VL - 57

SP - 1406

EP - 1412

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 6

ER -